The current study aims to develop and optimize microemulsions (ME) through Quality-by-Design (QbD) approach to improve the aqueous solubility and dissolution of poorly water-soluble drug disulfiram (DSF) for repurposing in melanoma and breast cancer therapy. The ME was formulated using Cinnamon oil & Tween 80, statistically optimized using a D-optimal mixture design-based QbD approach to develop the best ME with low vesicular size (Z) and polydispersity index (PDI). The DSF-loaded optimized stable ME showed enhanced dissolution, cytotoxicity and improved cellular uptake in B16F10 and MCF-7 cell lines compared with their unformulated free DSF. Our investigations suggested the potential of the statistically designed DSF-loaded optimized ME for repurposing melanoma and breast cancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11412148 | PMC |
| http://dx.doi.org/10.1080/20415990.2024.2363136 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beta-Blockers and Cutaneous Melanoma Outcomes: A Systematic Review and Random-Effects Meta-Analysis.
Pigment Cell Melanoma Res
January 2025
Dermatology Research Centre, Frazer Institute, The University of Queensland, Brisbane, Australia.
Beta-blockers have generated an exciting discourse for their potential as a cheap, safe, and effective adjunctive therapy for cutaneous melanoma patients, but the field remains murky. This systematic review investigates the association between beta-blocker use and survival outcomes in cutaneous melanoma patients. We reviewed 12 studies with 21,582 patients in a network meta-analysis and found a benefit between beta-blocker use and disease-free survival but no other significant association for melanoma-specific or overall survival.
View Article and Find Full Text PDFEditorial: Towards continued and affordable accessibility of innovative drugs: sustainable development and efficient use of medicines.
Front Pharmacol
November 2024
Department of Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands.
Antitumoral action of carvedilol-a repositioning study of the drug incorporated into mesoporous silica MCM-41.
Nanotechnology
November 2024
University of Franca; Av. Dr. Armando Salles Oliveira, 201, Pq. Universitário CEP 14404-600, Franca, SP, Brazil.
We have studied repositioning of carvedilol (an antihypertensive drug) incorporated into MCM-41 mesoporous silica. The repositioning proposes a reduction in the slow pace of discovery of new drugs, as well as toxicological safety and a significant reduction in high research costs, making it an attractive strategy for researchers and large pharmaceutical companies. We obtained MCM-41 bysynthesis and functionalized it by post-synthesis grafting with aminopropyltriethoxysilane (APTES) only or with folic acid (FA), which gave MCM-41-APTES and MCM-41-APTES-FA, respectively.
View Article and Find Full Text PDFExpression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.
Sci Rep
October 2024
Department of Immunology, Mayo Clinic, Jacksonville, FL, USA.
In this study, we tested a novel approach of "repurposing" a biomarker typically associated with breast cancer for use in melanoma. HER2/neu is a well characterized biomarker in breast cancer for which effective anti-HER2/neu therapies are readily available. We constructed a lentivirus encoding c-erb-B2, an animal (rat) homolog to HER2/neu.
View Article and Find Full Text PDFA High-Throughput Drug Repurposing Strategy to Treat TBX2 and/or TBX3 Dependent Cancers.
Cancer Med
October 2024
Division of Cell Biology, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Observatory, Cape Town, South Africa.
Background: The highly homologous T-box transcription factors TBX2 and TBX3 are critical for embryonic development, and their overexpression in postnatal tissues contributes to a wide range of malignancies, including melanoma and rhabdomyosarcoma. Importantly, when TBX2 and TBX3 are depleted in cancers where they are overexpressed, the malignant phenotype is inhibited, and they have therefore been regarded as druggable targets. However, the time and costs associated with de novo drug development are challenging and result in drugs that are costly, especially for patients in low- and middle-income countries.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!